Monday, 17 December 2018

Biocon's Bengaluru plant completes USFDA inspection without any observations

12 November 2018 | News

The audit concluded without any observations and no Form 483 was issued.

Biotechnology major Biocon said that the US health regulator has completed inspection of its new manufacturing facility in Bengaluru without any observations.

"The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection of our new oral solid dosage forms manufacturing facility at Biocon Park in Bengaluru from November 5-9, 2018," Biocon said in a regulatory filing.

The audit concluded without any observations and no Form 483 was issued, reported PTI.

A Form 483, is issued by the USFDA to notify a company's management of any objectionable conditions at its manufacturing facilities. It is issued to the management of a firm at the conclusion of an inspection.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Does Indian Pharma lack an innovation-friendly ecosystem?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls